Skip to main content
GLMD
NASDAQ Life Sciences

Nasdaq Extends Galmed's Deadline to Regain $1 Bid Compliance by 180 Days

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.621
Mkt Cap
$5.131M
52W Low
$0.411
52W High
$1.75
52W Position info
51% above low
Off High info
65% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

GLMD sits 51% above its 52-week low of $0.411 on light trading volume (0.2× avg).

Summary

After failing to meet the $1 minimum bid price rule in the first 180-day period, Galmed has been given until January 25, 2027 by Nasdaq to regain compliance. The stock currently trades at $0.62.


Key Events · Legal and Risk Events · GLMD

  • Nasdaq Extension Granted

    An additional 180-day compliance period has been granted by Nasdaq, giving Galmed until January 25, 2027 to meet the $1 minimum bid price rule.

  • Failed Initial Compliance Period

    The company did not regain compliance during the first 180-day period that ended July 28, 2026, following the deficiency notice received on January 29, 2026.

  • Compliance Requirement

    To satisfy the rule, the stock must close at or above $1 per share for at least 10 consecutive trading days before the deadline.

  • Current Price Gap

    With the stock at $0.62, a roughly 60% increase is needed to reach $1, and the price must hold there for 10 consecutive days.


Analysis · GLMD · Life Sciences

A crucial lifeline has been extended to Galmed: Nasdaq has pushed the deadline to January 25, 2027 for the stock to climb back above $1. The company was unable to remedy the shortfall during the initial 180-day window that closed on July 28. Trading at $0.62, the shares need a 60% rally and must hold at or above $1 for 10 consecutive days to avert delisting. While the extension provides breathing room, the clock is running—and recent positive pipeline developments have yet to spark a sustained price recovery.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GLMD was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.41 to $1.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GLMD - Latest Insights

GLMD
Sep 08, 2026, 6:08 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.30
Real-time Price: $4.66 info
Change: +$0.360 (+8%) info
Market Cap: $4.822M info
GLMD
Sep 02, 2026, 4:20 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $4.66 info
Change: +$0.541 (+13%) info
Market Cap: $4.822M info
GLMD
Aug 19, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.513
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.5145
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info
GLMD
Aug 17, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.5206
Real-time Price: $4.66 info
Change: Reverse Stock Split info
Market Cap: $4.822M info